S&P 500
7,589.40
+0.09%
Dow Jones
52,774.00
+0.11%
Nasdaq 100
29,578.00
+0.07%
Russell 2000
2,983.24
+0.06%
FTSE 100
10,492.80
+0.05%
Nikkei 225
67,232.60
-0.68%

Health and Healthcare

J&J, Pfizer Halt Development of Alzheimer’s Drug

Photo of 247sam
By 247sam Updated Published

Invalid Image
Johnson & Johnson Inc. (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimer’s after the drug failed a second clinical trial.

The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.

Johnson & Johnson will take a $300 million to $400 million charge in the third quarter.

Shares of Pfizer are down 2.51% in after-hours trading. Shares of Johnson & Johnson are up 0.21%.

Samuel Weigley

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of 247sam
About the Author 247sam →

Continue Reading

The List of Failed Alzheimer’s Drug Treatments Keeps Growing
Jon C. Ogg |

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech…

Paul Ausick |

Pfizer’s Alzheimer’s Drug Fails Trial

A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed…

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure
Jon C. Ogg |

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and…

Jon C. Ogg |

BioHealth Daily: Forgetting Alzheimers (PRAN, PFE, NVS, FRX)

It’s the BioHeath Daily for key developments in drugs, biotech, and medical developments.  Prana Biotechnology Ltd. (NASDAQ: PRAN) is often…

Paul Ausick |

Alzheimer’s Drug Shows Some Success (LLY, PFE, ELN)

Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company’s solanezumab treatment for Alzheimer’s disease failed to…

Douglas A. McIntyre |

Barron’s Alzheimer’s Article Only Scratches the Surface

Stock Tickers: WYE, NRMX, ELN, NVS, PFE, LLY, JNJ, AZN, TRGT, SNH, SRZ, BKD, ALC, HCR, ESC, MYGN, FRX, NYMX,…

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson
Chris Lange |

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson

24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case…

Jon C. Ogg |

Elan’s Spin-Off Creates Buyout Hopes (ELN, BIIB, ALKS, PFE)

Elan Corporation, plc (NYSE: ELN) may be surging on news that it is going to spin off its drug research unit,…

Douglas A. McIntyre |

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this…

Top Gaining Stocks

PayPal
PYPL • Vol: 91,051,931
BlackRock
BLK • Vol: 1,583,086
CBRE Group
CBRE • Vol: 1,908,902
CarMax
KMX • Vol: 4,715,131
Invesco
IVZ • Vol: 6,265,161

Top Losing Stocks

Pentair
PNR • Vol: 12,047,011
Erie Indemnity
ERIE • Vol: 641,455
Dell Technologies
DELL • Vol: 13,041,473
Progressive
PGR • Vol: 7,223,690
Western Digital
WDC • Vol: 7,926,134